Skip to main content
Caplight Logo









Lyfegen

Lyfegen

Private
BaselHealthcare & Life Scienceshttps://www.lyfegen.com/

Last Round

Series A

Extension

Dec 11, 2024

Total Funding Raised

$16.64M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Lyfegen is a health tech company that provides a software platform for access, pricing, and rebate management for health insurances, governments, and pharmaceutical companies.

Sector

Healthcare & Life Sciences

Verticals

Vertical SaaS, Healthcare Analytics, Compliance & Risk, Workflow Automation

Business Model

B2B

Customer Profile

Subscription SaaS, Services & Consulting

AI Layer

Application

Keywords

value-based contractingdrug pricingoutcome-based pricingrebate managementhealthcare SaaSpharma techhealthcare analyticscontract automationreal-world evidenceRWEpayer-provider solutionshealth techvertical SaaS

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Lyfegen Comparables

Compare Lyfegen with similar companies based on industry and business-model similarity.

Lyfegen comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Model N
68%
Datavant
67%
Accorded
66%

Lyfegen Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionDec 11, 2024
Series ASep 20, 2022
SeedSep 1, 2020
SeedApr 17, 2019

Key People

Founding team and executive leadership

Nico Julian Mros

Chief Customer Experience Officer & Founder

Founding Team

Girisha Fernando

CEO Founder

Founding Team

Lyfegen Investors

Notable investors and investment history

Lyfegen investors
InvestorRounds
APEX VenturesSeries A
aMoonSeries A Extension, Series A
TX VenturesSeries A Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 21, 2026

    Monthly visitors grew 115% MoM, reaching 4.7K.

  • Mar 3, 2026

    Launched AI Contracting Companion for drug access solutions.

Lyfegen Filings

Explore SEC and related filing metadata, where available.

Lyfegen filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Lyfegen's valuation, stock price, and market status.

Is Lyfegen a public or private company?

Lyfegen is a private company.

What is the current stock price of Lyfegen?

Lyfegen is a private company with no public stock price. No recent secondary market data is available.

How much is Lyfegen worth (valuation)?

Valuation information for Lyfegen is not publicly available.

Can I buy Lyfegen stock?

Lyfegen shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Lyfegen's last funding round?

Lyfegen's most recent funding round was Series A on December 11, 2024.

Who are the main investors in Lyfegen?

Key investors in Lyfegen include aMoon, TX Ventures.

Will Lyfegen IPO soon?

No public IPO plans have been announced for Lyfegen.

How can I track Lyfegen secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Lyfegen's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersBasel
Employee Range51
Year Founded2018
Last FundingDec 11, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?